Burns Matteson Capital Management’s Quest Diagnostics DGX Stock Holding History

Burns Matteson Capital Management’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-5,173	Closed	-$732K	–	155
2023 Q1	$732K	Sell	5,173 -593	-10%	-$84.8K	0.47%	43
2022 Q4	$902K	Buy	+5,766	New	+$829K	0.6%	30
2022 Q3	–	Sell	-6,801	Closed	-$904K	–	131
2022 Q2	$904K	Buy	+6,801	New	+$927K	0.64%	26
2022 Q1	–	Sell	-1,272	Closed	-$220K	–	133
2021 Q4	$220K	Buy	+1,272	New	+$194K	0.15%	115
2021 Q3	–	Sell	-3,965	Closed	-$523K	–	143
2021 Q2	$523K	Buy	+3,965	New	+$519K	0.41%	39

Other funds holding DGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Burns Matteson Capital Management's DGX Position: Q2 2023 in Review

Burns Matteson Capital Management sold out of Quest Diagnostics (DGX) in Q2 2023, closing a stake of 5,173 shares — an estimated $732K sold.

Burns Matteson Capital Management first reported a position in DGX in Q2 2021 and held it in 5 quarters. The position peaked at $904K in Q2 2022. 820 funds tracked by Wall St. Rank hold DGX as of Q2 2023.

Burns Matteson Capital Management reported no remaining Quest Diagnostics position as of Q2 2023 after selling out during the quarter.
Burns Matteson Capital Management sold 5,173 Quest Diagnostics shares in Q2 2023, an estimated $732K.
Burns Matteson Capital Management first reported a position in Quest Diagnostics in Q2 2021 and held it in 5 quarters.
Burns Matteson Capital Management's Quest Diagnostics position peaked at $904K in Q2 2022.
820 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2023.

Based on Burns Matteson Capital Management's 13F filing for Q2 2023, filed 12 Dec 2023.